- Home
- MCBS vs PHAR Comparison
MCBS vs PHAR Comparison
Compare MCBS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCBS
- PHAR
- Stock Information
- Founded
- MCBS 2006
- PHAR 1988
- Country
- MCBS United States
- PHAR Netherlands
- Employees
- MCBS N/A
- PHAR N/A
- Industry
- MCBS Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MCBS Finance
- PHAR Health Care
- Exchange
- MCBS Nasdaq
- PHAR Nasdaq
- Market Cap
- MCBS 745.5M
- PHAR 718.1M
- IPO Year
- MCBS 2019
- PHAR N/A
- Fundamental
- Price
- MCBS $27.08
- PHAR $10.45
- Analyst Decision
- MCBS Hold
- PHAR Strong Buy
- Analyst Count
- MCBS 1
- PHAR 3
- Target Price
- MCBS $34.00
- PHAR $30.00
- AVG Volume (30 Days)
- MCBS 30.6K
- PHAR 2.6K
- Earning Date
- MCBS 07-18-2025
- PHAR 07-31-2025
- Dividend Yield
- MCBS 3.38%
- PHAR N/A
- EPS Growth
- MCBS 30.91
- PHAR N/A
- EPS
- MCBS 2.58
- PHAR N/A
- Revenue
- MCBS $143,775,000.00
- PHAR $320,708,000.00
- Revenue This Year
- MCBS $16.00
- PHAR $13.31
- Revenue Next Year
- MCBS $31.75
- PHAR $7.68
- P/E Ratio
- MCBS $10.42
- PHAR N/A
- Revenue Growth
- MCBS 19.70
- PHAR 24.13
- 52 Week Low
- MCBS $24.00
- PHAR $6.65
- 52 Week High
- MCBS $36.15
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- MCBS 42.39
- PHAR 47.51
- Support Level
- MCBS $27.14
- PHAR $10.41
- Resistance Level
- MCBS $28.90
- PHAR $11.50
- Average True Range (ATR)
- MCBS 0.57
- PHAR 0.32
- MACD
- MCBS -0.12
- PHAR -0.17
- Stochastic Oscillator
- MCBS 14.55
- PHAR 2.26
About MCBS MetroCity Bankshares Inc.
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.